Chemotherapy for hepatocellular carcinoma: current status and future perspectives

Masafumi Ikeda(National Cancer Center Hospital East), Junji Furuse(Kanagawa Prefectural Hospital Organization), Chigusa Morizane(Tokyo National Hospital), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Hiroshi Ishii(Chiba Cancer Center), Takuji Okusaka(National Cancer Centre Japan)
Japanese Journal of Clinical Oncology
November 25, 2017
10.1093/jjco/hyx180
Cited by 274

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780